Research guides

Sermorelin (GHRH 1-29): what the research says

A former prescription medicine sold as Geref. The clinical evidence is in children with growth hormone deficiency, and it does not transfer to healthy adults.

Available in the catalogue

Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.

Sermorelin is one of the few compounds in this catalogue that was once a marketed medicine, which changes what kind of evidence exists for it — and also what that evidence is about.

What the molecule is

The first 29 amino acids of human growth hormone-releasing hormone: the shortest fragment that retains the full activity of the natural hormone. It has been published as GHRH (1-29), GRF (1-29) and under the brand name Geref.

Working upstream

It acts at the GHRH receptor on the anterior pituitary, prompting release of stored growth hormone. Because it works through the body's own control loop rather than supplying the hormone directly, negative feedback remains intact — the property that distinguishes GHRH analogues from administered growth hormone. That is a mechanistic difference with real consequences for how a pituitary responds, and it is the reason the class exists.

What the clinical record actually covers

The published clinical literature concerns children with idiopathic growth hormone deficiency, in two roles: as a diagnostic agent for testing whether a pituitary can respond at all, and as a treatment in that specific paediatric population. That is a narrow and well-defined body of evidence, and it is not evidence about healthy adults.

This distinction gets lost more often with sermorelin than with almost anything else here, because the phrase “approved medicine” attaches to the molecule while the approval attached to an indication, a formulation and a patient group. The product is no longer marketed in the United States.

What studies reported

Each entry states what a study examined and the model it used. Nothing below describes an outcome for a person.

Everything below is drawn from published research, and each entry names the model the study used. Approval status varies by compound and by country, and nothing described here is supplied as a medicine or for use in a person.

  1. Prakash & Goa (1999)BioDrugs · 12(2):139–57

    A review of sermorelin in the diagnosis and treatment of children with idiopathic growth hormone deficiency, covering its use as a test of pituitary responsiveness and as a therapy in that population.

    review of human clinical use Source

Adverse and null findings reported

No dedicated safety study has been published for this compound. That is not a finding that none exists — it means the question has not been asked in print, and the gaps below say so.

What the research does not establish

An absence cannot be cited, so these are stated plainly. They are the part of the picture that silence would otherwise hide.

  • The `adverse` list above is empty, and that means nobody has published the study rather than that the compound was found harmless. The clinical safety record that exists sits inside the paediatric growth hormone deficiency literature and was never generated in healthy adults.
  • No published randomised trial has tested sermorelin in healthy adults for any outcome. Every clinical claim about that population is an extrapolation from a different one.
  • The compound is no longer marketed in the United States. Withdrawal of a product is a commercial event and not in itself a safety finding, but it also means no ongoing pharmacovigilance is generating new data.
  • Because it depends on a pituitary that can respond, its activity varies with the state of the axis it acts on. That variability is documented in the diagnostic literature and is rarely mentioned when the compound is described.
  • Nothing has been published on sustained administration over long periods in any population.

Common questions

Was sermorelin ever an approved medicine?
Yes. It was marketed as Geref and used both to diagnose and to treat idiopathic growth hormone deficiency in children. It is no longer marketed in the United States.
How is sermorelin different from growth hormone?
It does not supply growth hormone. It acts at the GHRH receptor and prompts the pituitary to release its own, which leaves the body's negative feedback loop intact — the defining difference between GHRH analogues and administered growth hormone.
How does sermorelin differ from CJC-1295?
Both act at the GHRH receptor. CJC-1295 carries amino acid substitutions that resist enzymatic breakdown, so it persists longer; sermorelin is the unmodified 29-residue fragment and is cleared quickly.
Does the clinical evidence apply to healthy adults?
No. The published clinical work is in children with growth hormone deficiency. Applying it to healthy adults is an extrapolation across both age and pituitary status, and no trial has tested it.
Is sermorelin supplied here as a medicine?
No. It is supplied as a laboratory reagent for in-vitro research, with a certificate of analysis, and not for human or veterinary use.

Compounds covered

The reference page for each compound this article discusses.

Related articles

All guides